Quecitinib

Quecitinib (QY201) is an orally active JAK1/TYK2 dual inhibitor. Quecitinib is also a substrate of cytochrome P450 3A and is mainly metabolized to mono-oxide and glucuronidation products. Quecitinib has favorable pharmacokinetic properties as well as safety. Quecitinib can be used in the research of atopic dermatitis and other autoimmune diseases[1].

Product Specifications

CAS Number

[2416858-84-7]

Product Name Alternative

QY201

UNSPSC

12352005

Target

Cytochrome P450; JAK

Related Pathways

Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Inflammation/Immunology

Smiles

O[C@H](C)C1=NC2=CN=C(NC=C3)C3=C2N1N4CCC(CC#N)CC4

Molecular Formula

C17H20N6O

Molecular Weight

324.38

References & Citations

[1]Wang JY, et al. The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects. J Clin Pharmacol. 2025 May 27.